Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2005 1
2007 1
2008 3
2010 2
2013 5
2014 5
2015 4
2016 11
2017 13
2018 13
2019 16
2020 19
2021 12
Text availability
Article attribute
Article type
Publication date

Similar articles for PMID: 34301785

90 results
Results by year
Filters applied: . Clear all
Page 1
Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics.
Thapa P, Ranade R, Ostwal V, Shrikhande SV, Goel M, Basu S. Thapa P, et al. Nucl Med Commun. 2016 Oct;37(10):1030-7. doi: 10.1097/MNM.0000000000000547. Nucl Med Commun. 2016. PMID: 27243215
Pre-therapy Somatostatin Receptor-Based Heterogeneity Predicts Overall Survival in Pancreatic Neuroendocrine Tumor Patients Undergoing Peptide Receptor Radionuclide Therapy.
Werner RA, Ilhan H, Lehner S, Papp L, Zsótér N, Schatka I, Muegge DO, Javadi MS, Higuchi T, Buck AK, Bartenstein P, Bengel F, Essler M, Lapa C, Bundschuh RA. Werner RA, et al. Mol Imaging Biol. 2019 Jun;21(3):582-590. doi: 10.1007/s11307-018-1252-5. Mol Imaging Biol. 2019. PMID: 30014345
90 results